Agenus Inc

Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial, showing an estimated 48% three-year overall survival for botensilimab plus balstilimab in recurrent ovarian cancer. The estimate was unchanged from two years, with median overall survival of 14.8 months, a 23% objective response rate among 35 evaluable patients, and a median duration of response of 9.7 months. At last follow-up, 25% of the 44 patients who received at least one dose, 11 in total, were alive and off all therapy. The heavily pretreated population had received a median of four prior lines of therapy, 77% had received bevacizumab and 57% a PARP inhibitor, and nearly three-quarters had platinum-resistant or refractory disease; estimated three-year survival was 47% in that subgroup and 61% in the 17 patients whose disease had progressed on a PARP inhibitor. The data were presented by Rebecca L. Porter of Dana-Farber Cancer Institute at the 2026 International Gynecologic Cancer Society Annual Global Meeting in Montréal, and Agenus said no new safety signals or treatment-related deaths were reported.

Agenus now carries an updated implied fair value of about US$26.33 per share, up from US$19.50, a roughly 35% increase tied to trial updates and fresh financing. The higher target reflects recent Street commentary on the botensilimab plus balstilimab program in microsatellite stable colorectal cancer and on new capital that changes how investors weigh financing risk. Chardan, H.C. Wainwright and B. Riley have all assigned Buy ratings on the stock in 2026, with price target revisions to US$30, US$25 and US$14. H.C. Wainwright factors in an assumed issuance of 23 million shares tied to an US$85 million upfront financing payment, highlighting ongoing dilution and funding risk. The fair value update also reflects revenue growth assumptions of a decline of about 1.37%, a net profit margin easing from about 17.91% to about 17.63%, a future P/E shifting from about 58.6x to about 80.6x, and a discount rate moving from about 7.60% to about 7.69%.

Advanced Biomed shares rallied as much as 211% this week, leading a group of biotech gainers that also included Novocure, Medpace, and others. Advanced Biomed, which has not yet commenced commercial sales, soared from $6.71 to an intraday high of $20.87 before closing Thursday at $16.78, up 36.98% on the day. Novocure surged more than 28% after reporting second-quarter total net revenues of $183.6 million, a 16% year-over-year increase, and raising its full-year 2026 revenue guidance to $710 million to $725 million from a prior range of $690 million to $710 million. Medpace gained more than 14% following second-quarter revenue of $707.3 million, up 17.2% from the prior-year period, and a full-year 2026 revenue forecast of $2.805 billion to $2.885 billion. Other notable movers included SciSparc, up over 20% on no specific news, Agenus, up more than 11% after announcing an oversubscribed private placement of up to $340 million, and AgomAb Therapeutics, up more than 11% ahead of expected clinical data readouts.

Agenus is redirecting its Phase 3 colon-cancer strategy, discontinuing financial support for its BATTMAN study and making the planned ROBBIN trial its central development priority. The shift is backed by a private placement expected to provide about $85 million upfront, with potential gross proceeds of $340 million if accompanying warrants are fully exercised. The company plans to direct the financing toward ROBBIN, a randomized global Phase 3 study of botensilimab plus balstilimab in patients with high-risk Stage II and Stage III microsatellite-stable colon cancer, with the first patient expected to be dosed in the first quarter of 2027. Agenus shares were recently trading at $6.46, up 93.1% from the July 10 close, after reaching $8.70 earlier in the session. The upfront portion of the transaction is expected to support operations into the third quarter of 2027, while full warrant exercise could extend the cash runway through the end of 2031.

Q32 Bio led biotech gainers Monday with shares soaring over 90% after its Phase 2 SIGNAL-AA trial of Bempikibart in severe alopecia areata showed 40% of patients in the modified intent-to-treat group achieved 20% or less scalp hair loss by Week 36. The company plans a registration-directed program in the first half of 2027 and also announced a $200 million public offering. Agenus jumped over 82% after entering an $85 million private placement to fund its planned Phase 3 ROBBIN1 trial of botensilimab and balstilimab in MSS colon cancer, with first patient dosing expected in early 2027. Actuate Therapeutics gained over 23% following last month's news that its drug Elraglusib will be evaluated in the BEACON2 pediatric neuroblastoma trial. Galectin Therapeutics rose over 13% after reaching an FDA agreement on the primary endpoint for its Phase 3 study of Belapectin in MASH cirrhosis. Amwell and Shoulder Innovations each gained over 11% on no specific news, with Amwell expecting second-quarter revenue of $48 million to $52 million and Shoulder Innovations raising its full-year revenue guidance to between $65 million and $68 million.

Agenus shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab immunotherapy combination in microsatellite-stable colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants. The transaction was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. Proceeds will be used to advance ROBBIN, a planned registrational Phase 3 trial evaluating neoadjuvant BOT+BAL in previously untreated high-risk Stage II and Stage III MSS colon cancer, with the company expecting the financing, assuming full warrant exercise, to provide funding through the end of 2031. The trial is designed to enroll 850 patients globally and will compare neoadjuvant BOT+BAL followed by standard of care against standard of care alone, with event-free survival as the primary endpoint.

U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space. Agenus surged 13% after the biotechnology company announced an $85 million private placement led by Commodore Capital, with participation from several life sciences investors. The financing could increase to as much as $340 million if all purchase warrants are exercised, with the proceeds earmarked to fund the company's Phase 3 ROBBIN trial and extend its cash runway through the end of 2031. Micron Technology fell 5.1% after shares of South Korean memory-chip maker SK Hynix plunged more than 15% in Asia, triggering a broader selloff across the memory sector. Western Digital dropped 5.4% as the weakness in memory and storage stocks spread across the sector.